eGenesis develops genetically engineered porcine (pig) kidneys and other organs that are compatible with human bodies, aiming to address the organ shortage by enabling transplantations into humans. Its product is created by editing pig genes to reduce rejection and improve compatibility, producing HuCo™ (Human Compatible) organs and cells that can be transplanted by healthcare providers. Unlike many biotech firms that focus on synthetic tissues or other approaches, eGenesis concentrates on xenotransplantation—using animal organs engineered to be accepted by the human immune system—for use in patients awaiting transplants. The company’s goal is to save lives and improve quality of life by expanding the supply of transplantable organs and reducing wait times for patients in need.
Company Size
51-200
Company Stage
N/A
Total Funding
$472.7M
Headquarters
Cambridge, Massachusetts
Founded
2015
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?